About OKYO OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain and dry eye disease, with ...
Chemotherapy appears to activate a stress-sensing system inside immune cells. According to new research from Weill Cornell Medicine and Wake Forest ...
Researchers discovered that chemotherapy can accidentally trigger a stress alarm in immune cells, causing inflammation that ...
Chemotherapy activates a stress sensor in immune cells, triggering inflammation and nerve damage, which may help explain why many cancer patients experience debilitating pain as a side effect, ...
OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with ...
Describes the nature of a clinical study. Types include: Observational study — observes people and measures outcomes without affecting results. Interventional study (clinical trial) — studies new ...
NMNAT2 is a key protein required for axon integrity whose rapid depletion following axon injury triggers Wallerian ...
Zacks Small Cap Research on MSN
DWTX: Interim Readout for Halneuron® Phase 2b Trial in CINP in 4Q25…
DWTX READ THE FULL DWTX RESEARCH REPORT Business Update 100 Patients Enrolled in Phase 2b Trial of Halneuron®; Interim Analysis in 4Q25 Dogwood Therapeutics, Inc. (NASDAQ:DWTX) is currently conducting ...
Revenue -- Reported at $3.7 million for the three months ended September 30, 2025, up from $2.3 million in the same period in 2024; the increase was due to a $1.5 million rise in license revenues, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback